This activity is intended for oncologists, gastroenterologists, and surgeons.
The goal of this activity is to discuss the evolving role of cancer immunotherapy in gastric and gastroesophageal junction cancer.
Approximate Time to Complete: 30 minutes
Credit Available: Nov. 29, 2017 - Nov. 29, 2018
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the clinical trial data on the use of immune checkpoint inhibitors in advanced gastric cancer
- Have increased knowledge regarding the which patients with advanced gastric cancer may be appropriate candidates for immune checkpoint modulation.